{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058635","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.574695+00:00","generated_at":"2026-06-02T02:26:18.656080+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spruce Biosciences Q1 net loss $11.6M; cash $81.2M; CAHmelia-204 data expected Q3 2024","bullets":["Cash and cash equivalents $81.2M as of March 31, 2024; expected to fund operations through end of 2025.","Net loss of $11.6M vs $12.8M in Q1 2023; R&D expenses $10.3M (down from $11.7M).","Collaboration revenue of $2.0M from Kaken Pharmaceutical agreement.","CAHmelia-203 analyses show higher GC dose and drug compliance correlate with larger A4 reductions.","Topline data from CAHmelia-204 (adult CAH) and interim dose-ranging from CAHptain-205 (pediatric) expected Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058635","json":"https://secwatch.observer/filing/0000950170-24-058635.json","markdown":"https://secwatch.observer/filing/0000950170-24-058635.md","text":"https://secwatch.observer/filing/0000950170-24-058635.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024058635/0000950170-24-058635-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024058635/sprb-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:26:18.656080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"875380fa5b6b6a21379543867a52fc96ddf874f3","claim":"SPRUCE BIOSCIENCES, INC. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024058635/0000950170-24-058635-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}